Regensight will join the most important and awaited International Annual Conference in corneal and cataract surgery organized by ESCRS in Barcelona (https://congress.escrs.org/) on 6-10 September 2024.
With validation of theranostics in the randomized multicenter clinical trial ARGO, Regensight is introducing a revolutionary paradigm shift in Ophthalmology for management of keratoconus.
At ESCRS 2024, you will learn about theranostics, combining molecular imaging diagnostics and UV-A light triggered therapeutics, allowing for predictive, personalized and precise treatment of keratoconus offering predictable outcomes to patients with 91% accuracy and 95% precision.
Stay tuned for our latest news and follow us on linkedin https://www.linkedin.com/company/regensight/